Saltoro Capital’s Yarrow Bioscience YARW Stock Holding History

Saltoro Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$571K	–	154
2020 Q4	$571K	Buy	+100	New	+$628K	0.28%	70

Other funds holding YARW

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Saltoro Capital's YARW Position: Q1 2021 in Review

Saltoro Capital sold out of Yarrow Bioscience (YARW) in Q1 2021, closing a stake of 100 shares — an estimated $571K sold.

Saltoro Capital first reported a position in YARW in Q4 2020 and held it in 1 quarter. The position peaked at $571K in Q4 2020. 81 funds tracked by Wall St. Rank hold YARW as of Q1 2021.

Saltoro Capital reported no remaining Yarrow Bioscience position as of Q1 2021 after selling out during the quarter.
Saltoro Capital sold 100 Yarrow Bioscience shares in Q1 2021, an estimated $571K.
Saltoro Capital first reported a position in Yarrow Bioscience in Q4 2020 and held it in 1 quarter.
Saltoro Capital's Yarrow Bioscience position peaked at $571K in Q4 2020.
81 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q1 2021.

Based on Saltoro Capital's 13F filing for Q1 2021, filed 14 May 2021.